Amitkumar Nitinkumar Mehta

11PUBLICATIONS
83CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursDiagnostic radiographyCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

|Feb 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Sep 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Joseph E Maakaron, Adam Asch, Leslie Popplewell

|Aug 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.

Amitkumar Mehta, Leslie Popplewell, Graham P Collins

|Dec 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).

Tycel J Phillips, Abraham Avigdor, Ronit Gurion

Pageof 2

Frequent Collaborators

4 joint publications

Nilanjan Ghosh

4 joint publications

Reem Karmali

4 joint publications

Izidore S Lossos

3 joint publications

Diego Villa